dementia Archives

Pharmalot Ed Silverman

Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug

Health Lauren Gravitz

Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s

Biotech Adam Feuerstein

FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants

Biotech Jason Mast

As FDA considers new Alzheimer’s drug, a case study details safety concerns

The Aduhelm Files Rachel Cohrs

‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

Politics Bob Herman

Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug

Biotech Matthew Herper and Allison DeAngelis

‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug

Biotech Jonathan Wosen and Damian Garde

Alzheimer’s researchers try out an unfamiliar sensation: optimism

Biotech Damian Garde and Jonathan Wosen

Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments

First Opinion Madhav Thambisetty

Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage

Biotech Allison DeAngelis

Axsome drug reduces agitation in Alzheimer’s patients, data show

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Roche’s failure, Eisai’s success, and a live AMA

Biotech Adam Feuerstein, Jason Mast and Damian Garde

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

Health Usha Lee McFarling

Brains of Black Americans age faster, study finds, with racial stressors a likely factor

First Opinion Poul Høilund-Carlsen, Abass Alavi and Jorge R. Barrio

Better access to amyloid-PET scans won’t reduce racial inequities in Alzheimer’s disease

Biotech Adam Feuerstein and Damian Garde

Roche’s experimental Alzheimer’s treatment fails to slow cognitive decline across two clinical trials

Health Usha Lee McFarling

Cuando el cuidado es un asunto familiar, el Alzheimer supone una pesada carga para los hijos y los cónyuges

Health Usha Lee McFarling

En la frontera entre Texas y México, nace un audaz plan para diversificar la investigación sobre el Alzheimer

Health Andrew Joseph

‘Front of the line’: For Alzheimer’s patients in successful trial, a feeling of gratitude

Biotech Adam Feuerstein and Damian Garde

What to know about Roche’s experimental Alzheimer’s treatment

First Opinion Jason Karlawish

How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

Biotech Adam Feuerstein, Damian Garde and Rachel Cohrs

Burning questions left unanswered about the latest Alzheimer’s therapy

Health Andrew Joseph

dementia

Most Read

In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments

FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation

Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference

Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny

Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups

Better access to PET scans can help reduce racial inequities in Alzheimer’s disease

All Coverage

Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug

Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s

FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease

Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants

As FDA considers new Alzheimer’s drug, a case study details safety concerns

‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug

‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug

Alzheimer’s researchers try out an unfamiliar sensation: optimism

Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments

Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage

Axsome drug reduces agitation in Alzheimer’s patients, data show

Listen: Roche’s failure, Eisai’s success, and a live AMA

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

Brains of Black Americans age faster, study finds, with racial stressors a likely factor

Better access to amyloid-PET scans won’t reduce racial inequities in Alzheimer’s disease

Roche’s experimental Alzheimer’s treatment fails to slow cognitive decline across two clinical trials

Cuando el cuidado es un asunto familiar, el Alzheimer supone una pesada carga para los hijos y los cónyuges

En la frontera entre Texas y México, nace un audaz plan para diversificar la investigación sobre el Alzheimer

‘Front of the line’: For Alzheimer’s patients in successful trial, a feeling of gratitude

What to know about Roche’s experimental Alzheimer’s treatment

How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

Burning questions left unanswered about the latest Alzheimer’s therapy

An Alzheimer’s therapy scores winning results, but what could it mean for patients?

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day